Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

Karam Khaddour1,2*, Sandra L. Gomez-Perez3, Nikita Jain1, Jyoti D. Patel4 and Yanis Boumber4,5

1 Department of Medicine, Rosalind Franklin University of Medicine and Science, McHenry, IL, United States, 2 Department of Medicine, Division of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL, United States, 3 Department of Clinical Nutrition, Rush University Medical Center, Chicago, IL, United States, 4 Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, United States, 5 Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia

Body composition refers to the proportional content of body fat mass and lean body mass that can lead to a continuum of different phenotypes ranging from cachectic/sarcopenic state to obesity. The heterogenetic phenotypes of body composition can contribute to formation of some cancer types and can sometimes lead to disparate outcomes. Both of these extremes of the spectrum exist in patients with non-small cell lung carcinoma (NSCLC). The discovery of new pathways that drive tumorigenesis contributing to cancer progression and resistance have expanded our understanding of cancer biology leading to development of new targeted therapies including tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) that have changed the landscape of NSCLC treatment. However, in the new era of precision medicine, the impact of body composition phenotypes on treatment outcomes and survival is now being elucidated. In this review, we will discuss the emerging evidence of a link between body composition and outcomes in patients with NSCLC treated with TKI and ICI. We will also discuss suggested mechanisms by which body composition can impact tumor behavior and anti-tumor immunological response.

Keywords: non-small cell lung cancer, body composition, obesity, sarcopenia, tyrosine kinase inhibitor, immune checkpoint inhibitor, overall survival

Abbreviations: ALK, anaplastic lymphoma kinase gene; BMI, body mass index; CI, confidence interval; cm, centimeter; CT, computed tomography; CTLA-4, cytotoxic associated lymphocyte antigen-4; DEXA, dual-energy x-ray absorptiometry; EGFR, epidermal growth factor receptor; HR, hazard ratio; HU, Hounsfield unit; IARC, international agency for research on cancer; ICI, immune checkpoint inhibitor; IL-6, interleukin-6; IL-10, interleukin-10; IL-15, interleukin-15; IMAC, Intermuscular adipose content; irAEs, immune related adverse events; kg, kilogram; L3, third lumbar; m, meter; NA, not available; NK, natural killer; NR, not reached; PD-L1, programmed death 1; PD-L1, programmed death-ligand-1; PFS, progression free survival; PMI, psoas muscle index; N, number; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; SMI, skeletal muscle index; SCFM, subcutaneous fat mass; STAT3, signal transduction and activator of transcription 3; TGF-β, transforming growth factor-β; TKI, tyrosine kinase inhibitor; Treg, T-regulatory; TTF, time to treatment failure; VSR, visceral to subcutaneous adipose tissue area ratio; WHO, world health organization.
INTRODUCTION

Body composition refers to the proportional distribution of different body mass contents amongst various compartments including adipose tissue and lean body mass. The most clinically distinct body phenotypes are obesity and sarcopenia. Obesity plays a significant role in tumorigenesis. It is believed that some cancers develop in obese individuals because of the chronic meta-inflammation associated with obesity in which an abundance of hormones and cytokines can potentiate epithelial cell proliferation and cancer formation (1). The link between obesity and cancer development in multiple tumor types has long been recognized in multiple epidemiological studies including a landmark report by the International Agency for Research on Cancer (IARC) showing an increased incidence of several solid and hematological malignancies in obese patients compared to the general population (2). Interestingly, this link is weak in the case of lung cancer (2).

In addition to its role in cancer development, obesity has now emerged as a prognostic factor that may predict cancer mortality (3–5). Obesity can be associated with either inferior or superior outcomes, depending on the cancer type. For example, systematic reviews and meta-analyses of population-based follow-up studies of obese patients with non-metastatic prostate and breast cancer across all clinical stages found a higher mortality in obese compared to normal weight patients regardless of treatment modality (4, 5). Surprisingly, obese and overweight patients with lung cancer seem to have better survival rates compared to normal weight subjects with a relative risk (RR) of 0.78 (95% CI: 0.75–0.82) in overweight and 0.79 (95% CI: 0.73–0.86) in obese patients respectively, however, this only applies to smokers (3). Moreover, a more recent Chinese study confirmed a strong inverse relationship between body mass index (BMI) and lung cancer mortality, which was again seen primarily in smokers (6).

The favorable effect of obesity on mortality in patients with non-small cell lung cancer (NSCLC) which is the most common type of lung cancer has been demonstrated in patients with local and metastatic disease who received different treatment modalities including surgery, radiation, and chemotherapy (7, 8). For example, Yang et al. demonstrated that obesity was associated with longer survival in lung cancer patients (N= 14,751) which was consistent among all stages (local, regional and distant) (7) Furthermore, a large retrospective study showed a trend for better survival in obese patients with NSCLC treated with combination doublet chemotherapies (N= 2,585) (9).

The other clinically distinct phenotype of body composition is sarcopenia which is defined by severe reduction of lean body mass and wasting of skeletal muscle. Sarcopenia has been identified as an independent prognostic factor for mortality in some cancer types including NSCLC (10, 11). In addition, a distinct overlap syndrome of increased adipose tissue (obesity) and loss of lean body mass (sarcopenia) has been recognized as an important factor contributing to worse prognosis in some cancers including NSCLC (12). These effects of obesity on mortality and worse prognosis in the presence of sarcopenia in cancer patients have generated an unprecedented interest in the field of oncology to study the interconnection between body composition phenotypes and cancer behavior including NSCLC (which will be the focus of this review) in an attempt to solve this conundrum. What adds to the importance of analyzing this association is that lung cancer has the highest prevalence, annual incidence and mortality rates worldwide compared to all cancer types in men and women (13). Likewise, body composition phenotypes such as obesity and sarcopenia are prevalent in lung cancer patients. As an example, up to 43% of patients with NSCLC cancer can develop sarcopenia and cachectic syndrome (14) and approximately about half of NSCLC patients are considered to have a BMI >25 mg/m² (considered overweight or obese) (15).

Recently, there has been a revolution in our understanding of lung cancer biology with the detection of driver mutations such as epidermal growth factor receptor (EGFR) mutation as well as the exploration of the role of immune system dysfunction in cancer progression (16–18). These discoveries have transformed the outcomes of advanced lung cancer with the development of tyrosine kinase inhibitors (TKI) targeting driver mutations such as EGFR directed TKIs and immune checkpoint inhibitors (ICI) which unleash the host immune system against tumor cells (19–24). This recent development of therapeutics in NSCLC was accompanied by a huge effort to identify patients who benefit the most from these medications given that a significant proportion of patients do not respond (25). Given the established link between different body composition and outcomes in NSCLC that was outlined by prior research, it was plausible for researchers to analyze whether different body phenotypes could be a predictive factor for response and outcomes with novel therapies.

With an evolving landscape of treatment options in advanced and metastatic lung cancer, it is imperative to further understand if body composition phenotypes can predict response and outcomes to these new classes of medications and whether there is a mechanistic effect of proportionate body components and tumor microenvironment. In this review, we first introduce the common approaches used in clinical research to estimate body composition including obesity and sarcopenia. Next, we discuss the available evidence of a biological crosstalk between different body composition phenotypes and tumor microenvironment in NSCLC. Lastly, we highlight the available studies conducted to analyze the implications of body composition phenotypes on survival outcomes in patients with NSCLC who were treated with either EGFR TKI or ICI; we also provide our recommendations on the conceptual utility of incorporating body composition calculations into prospective trials.

DISCUSSION

Methods Used To Estimate Body Composition in Patients With Non-Small Cell Lung Cancer

Many measures have been used in recent and ongoing research investigating the effect of body composition phenotypes on...
cancer outcomes including NSCLC. The most conventional and easiest method of estimating body composition to identify obesity is through calculation of BMI which is defined by weight divided by the square of body height [kg/m²]. Based on the world health organization (WHO) classification, individuals can be divided into six groups to estimate the degree of obesity (Table 1) (26, 27). However, the complexity and heterogeneity of body composition and nutritional status might not be reflected accurately with the use of BMI alone due to its low sensitivity as indicted by discrepancies between BMI and central obesity (15, 28). In addition, calculation of BMI does not offer an accurate depiction of lean body mass which, when reduced, is considered an independent prognostic factor for high mortality in patients with NSCLC (10, 11). It has also been recognized that a subset of obese patients (defined by BMI > 30 kg/m²) are considered to be metabolically healthy whereby they are considered to have a favorable distribution of fat mass with a normal inflammatory profile which potentially reduces the risk incurred by diseases related to obesity such as cancer and cardiovascular disease (29).

Moreover, the calculation of BMI cannot distinguish between different patterns of body fat distribution (subcutaneous versus visceral) which could lead to multiple heterogeneous obesity phenotypes that could be associated with different biology and are not accurately reflected by BMI (30). Lastly, definition of obesity based on WHO classification can vary depending on ethnicity (26). This has led to the utilization of other indicators and calculations of adipose tissue content to study their relationship with outcomes in NSCLC patients such as visceral fat mass, subcutaneous fat mass, visceral to subcutaneous ratio, and fat mass index among others (31).

The measurement of sarcopenia is based on calculation of skeletal muscle index (SMI) (32, 33). Calculation of SMI is defined as total cross-sectional skeletal muscle mass (cm²) normalized by height (m²). Skeletal muscle mass also referred to as skeletal muscle area is derived from the total skeletal muscle mass of the eight abdominal muscles (psoas, erector spinae, quadratus lumbarum, transversus abdominis, latissimus dorsi, external, and internal obliques, and rectus abdominis) measured by surface area (cm²) at the third lumbar (L3) landmark using a single cross-sectional computed tomography (CT) image (32, 34). The L3 landmark is visible in CT scan protocols routinely performed for diagnostic and monitoring reasons in most cancer populations: abdomen (T10-L4), chest- abdomen (T1-L4), or chest-abdomen-pelvis (T1-L5). The use of a single CT image for regional body composition analysis at L3 has been described and validated in great detail in several seminal papers (32, 34, 35). The most valuable feature of this L3 landmark is that it is linearly related to whole-body fat free mass, appendicular skeletal muscle mass and whole-body fat mass as measured by dual-energy x-ray absorptiometry (DXA) in non-cancer and cancer populations (34). In brief, the CT scanner differentiates between adipose, skeletal muscle, and other compartments like bone based on specific attenuation thresholds according to the CT unit of measurement, the Hounsfield unit (HU) scale (e.g., skeletal muscle attenuation threshold is -29 to 150 HU). Cross-sectional tissue surface areas (cm²) are semi-automatically determined by a medical imaging software such as SliceOmatic v 5.0 (Tomovision Montreal, Quebec, Canada) based on HU tissue-specific thresholds (34, 35) (Figure 1). Then, tissue boundaries are manually corrected as needed by a trained investigator following the semi-automatic analysis. Cutoff points for sarcopenia using the L3 SMI according to ethnicity, gender and BMI (sarcopenic obesity) have been validated with adverse cancer-related outcomes in several studies (32, 33).

Sarcopenic obesity is defined as low skeletal muscle mass (i.e., sarcopenia) according to a SMI cut-off such as <38.5 cm²/m² for women and <52.4 cm²/m² for men in the context of a BMI > 30 kg/m² as published by Prado et al. (32). Similarly, sarcopenia and sarcopenic obesity can also be determined using BMI and SMI specific cut-offs for men (SMI < 43 cm²/m² for underweight and normal weight men, SMI < 53 cm²/m² for overweight and obese men) and for women (SMI <41 cm²/m² across all BMI categories) as published by Martin et al. (33). Although the Martin et al. and Prado et al. SMI cut-off values have been used extensively by other investigators, there is currently no consensus on CT-derived SMI reference cut-off values to identify sarcopenia or sarcopenic obesity in healthy and clinical populations and is an active area of research. In addition, the L3 landmark may not be ideal for assessing SMI in patients with lung cancer, including NSCLC, who often only undergo chest CT scans (i.e., L3 vertebral landmark often not visible, T1-L1). Several research studies have examined alternative chest CT scan landmarks including lumen one (L1) and two (L2) and have provided potential SMI cut-offs for sarcopenia in healthy and in lung cancer populations, however these landmarks have not been adequately tested or validated particularly in large racially diverse cancer populations (35–38). Thus, identifying an appropriate and valid single vertebral landmark from a chest CT scan and derivation of specific cut-offs at these newer landmarks to identify sarcopenia also remains an emerging area of research.

Various researchers have used single muscle groups to determine sarcopenia such as the psoas muscle index (PMI) also usually at the L3 region (39) (see Figure 1). The major advantage of using a single muscle group is the speed by which this analysis can be conducted in comparison to having to capture all the muscle groups at this landmark. A major criticism for the use of single muscle groups is that it does not correlate with total lumbar skeletal muscle area and thus not representative of the entirety of the lumbar muscle groups and more importantly appears to be a poor indicator of clinical

### Table 1

| Body Mass Index (BMI) (kg/m²) | Definition            |
|-----------------------------|-----------------------|
| <18.5                       | Underweight           |
| 18.5 – 24.9                 | Normal weight         |
| 25.0 – 29.9                 | Overweight (Pre-obesity) |
| 30.0 – 34.9                 | Obesity class 1       |
| 35.0 – 39.9                 | Obesity class 2       |
| ≥40                         | Obesity class 3       |

*BM1 cut-off points used to define obesity can vary depending on ethnicity (26).*

---

Khaddour et al. Body Composition and Non-Small Cell Lung Cancer

Frontiers in Oncology | www.frontiersin.org October 2020 | Volume 10 | Article 576314
Chemotherapy (7, 45). This effect can be explained partially by advanced NSCLC patients who are treated with surgery or obesity is considered a protective factor in both early stage and Immune Response?

What Is the Effect of Obesity on Non-Small Cell Lung Cancer and Anti-Tumor

outcomes in cancer populations (40, 41). Given these limitations, the use of PMI is less favorable than the well-established and validated technique using total lumbar skeletal muscle area for the calculation of SMI as previously described.

The importance of identifying sarcopenia comes from the fact that it has high prevalence across all BMI subtypes as well as having a detrimental prognostic effect on patients with NSCLC (42, 43).

As previously mentioned, an overlap syndrome of sarcopenia and obesity (sarcopenic obesity) has been identified and associated with adverse clinical implications in different cancer types, including NSCLC. For example, an observational study of patients with NSCLC who were treated with chemotherapy found that patients with sarcopenic obesity had shorter overall survival (OS) compared to obese patients without sarcopenia (44). The variable methodologies used to estimate body composition from obesity to sarcopenia and their effect on cancer progression and outcomes pose a challenge on how to compare and derive conclusions from studies in NSCLC. Nevertheless, the effort to analyze the effect of different elements of body composition and outcomes in NSCLC is of much importance, as each phenotype could have distinct biological implications on the host and the tumor.

**What Is the Effect of Obesity on Non-Small Cell Lung Cancer and Anti-Tumor Immune Response?**

Obesity is considered a protective factor in both early stage and advanced NSCLC patients who are treated with surgery or chemotherapy (7, 45). This effect can be explained partially by the fact that obese patients who receive chemotherapy tend to develop less medication related toxicities leading to lower discontinuation rates of cancer treatment (46). However, the biological landscape associated with obesity seems to be more complex and is believed to play a role in cancer behavior and progression. As an example, some hormonal factors in obese patients such as leptin plasma levels can affect prognosis in NSCLC, as low leptin levels correlate with shortened OS (47). Inversely, adiponectin, which is another hormone secreted from the adipose tissue has been suggested as a factor contributing to tumor progression in NSCLC, but biological mechanisms explaining the action of this hormone are not well understood (48). Different body composition phenotypes in obese patients and their variable hormonal and inflammatory profiles have led to distinguishing obesity as “metabolically unhealthy obesity” versus “metabolically healthy obesity” whereby patients can have a high BMI consistent with obesity definition but have a favorable fat distribution with decreased systemic inflammation leading to low disease morbidity (29).

The biological and immunological aspects of the inverse relationship between obesity and prognosis in NSCLC, termed “obesity paradox” can be explained through several mechanisms (49). Obesity can lead to exhaustion of T-cells resulting in increased tumor growth and it can upregulate programmed death-1 (PD-1) expression on CD8+ T-cells in tumor mice models (50). PD-1 receptors are checkpoint protein receptors present on immune cells that when bound to their respective ligand receptor can decrease anti-tumor efficacy of the host immune system against tumor cells (51). Although, the mechanism by which obesity can increase PD-1 expression has not been fully elucidated, increased levels of leptin secreted from adipose tissues has been suggested to boost cascade signaling indirectly through signal transduction and activator of transcription 3 (STAT3) which leads to upregulation of PD-1 receptors on T-cells (Figure 2). This can, in part, explain the improved response rates and survival noted in patients with obesity.
obesity across different tumor types who are treated with ICI including PD-1/PD-L1 (programmed death ligand-1) inhibitors that target the interaction of these checkpoint receptors (52–54). Moreover, obesity can modulate other T-cell subsets such as T-regulatory (Treg) cells which function as immunosuppressant cells and when down regulated in obese patients, they can reduce production of interleukin-10 (IL-10) which leads to exacerbation of the chronic inflammatory state (55). Similarly, Treg cells have been found in the tumor microenvironment of NSCLC and lead to an inhibitory effect on effector T-cell proliferation (56). Therefore, the effect of obesity on Treg cells can play a role in modulating Treg response in NSCLC although this has not been studied yet. Another type of immune cell that is important in obesity and NSCLC are the Natural Killer (NK) cells which are responsible for innate immunity and anti-cancer function. NK cells have been shown to be impaired in patients with obesity (57). Likewise, NSCLC patients can lack the cytotoxic effect of NK cells and have defective granulation leading to decreased innate anti-tumor response (57–59). Finally, obesity can affect the balance between macrophage subtypes (M1- M2) favoring the M1 subtype (pro-inflammatory cells) over M2 (immunosuppressive and pro-tumorigenic) (60). An increase in M2 macrophages can lead to increased host immunosuppression and more aggressive tumor behavior which could theoretically explain the improved outcome profile noted in patients with NSCLC who are obese (61) (Table 2). This collective evidence suggests an alteration of anti-tumor immune function and the favorable outcomes in obese patients with NSCLC which can partially mechanisms of action through other immune cells such as NK cells and macrophages (65, 66).

What is the Effect of Sarcopenia on Non-Small Cell Lung Cancer and Anti-Tumor Immune Response?

Sarcopenia is usually considered to be a consequence of the changes accompanying malignancy such as malnutrition and alterations in the hormonal milieu including the surge of cytokines due to the presence of the tumor (67). However, the presence of sarcopenia which is manifested by reduced lean body mass including decreased skeletal muscle mass is believed to influence host immune system leading to immune senescence (68). Hence, sarcopenia can have a deleterious effect on the anti-tumor response mediated by the immune system. Also, altered cytokines levels such as elevated IL-6 and decreased IL-15 can affect immune cell function. For example, skeletal muscle cells are essential producers of IL-15 which have a positive effect on NK cell expansion, proliferation and cytotoxic effects (63, 64, 69). As such, subclasses of NK cells express PD-1 receptors and their downregulation in sarcopenia can partially explain the decreased response and worse outcomes in NSCLC patients treated with ICI (70, 71) (Figure 3). It should be noted that although the role of NK cells in prognosis of NSCLC patients has been suggested, the mechanism behind their role in the tumor microenvironment in lung cancer is still not well-defined (75). Similarly, it has been found that in IL-15 deficient mice models there is a reduction in the presence of CD8+ which suggests that lack of IL-15 can lead to less targetable cytotoxic T-cells by ICI (62, 76). In addition, the levels of IL-6 are increased in sarcopenic patients which can
contribute to tumor growth and alters the function of immune cells including T-cell subsets (77). The possible role the pleiotropic effect of IL-6 on the immune system has tempted researchers to study the effect of targeting this proinflammatory pathway in combination with PD-1 blockade and preclinical results have shown a synergistic effect on T-cell trafficking and antitumor immunity (78). Likewise, the levels of transforming growth factor-β (TGF-β) are altered in association with sarcopenia and have been found to have a negative effect on the regulation of immune system leading to T-cell exhaustion and dysfunctional NK cells (72–74) (Table 2). This cumulative interconnection between sarcopenia and immune dysregulation has also been examined as in obesity to determine whether lower lean body mass impacts the response and prognosis in patients with NSCLC.

The evidence of an existing molecular and pathological relationships between different components of body composition and improved outcomes in obese and non-sarcopenic patients has been described in several retrospective studies and meta-analyses (39, 79, 80). In the following sections, we will summarize the current evidence of the impact of body composition phenotypes and cancer-related outcomes in patients with NSCLC treated with TKI-EGFR or ICI.

### Table 2 | Immune cell modulation in obesity, sarcopenia and non-small cell lung cancer.

| Immune Cell Type | Modulation of immune cells, cytokines in Obesity | Modulation of immune cells, cytokines in Sarcopenia | Modulation of immune cells, cytokines in NSCLC | Reference |
|------------------|-----------------------------------------------|------------------------------------------------|-----------------------------------------------|-----------|
| T-Cell CD8+      | ↑ CD8+/CD4+ ratio                              | ↓ IL-15                                        | ↑ PD-1 expression on CD8+                     | 50, 62    |
| Treg             | Dysregulated Treg                              | ↓ IL-10                                       | ↑ Treg (immunosuppression)                     | 55, 56    |
|                  | ↑ Immunosuppression                             | NA                                            | ↑ CTLA-4                                       |           |
| NK Cells         | ↓ Cytotoxic NK cells                            | ↓ IL-15                                       | ↓ NK Degranulation                             | 55–59, 63 |
|                  | NA                                            | ↓ NK cell activity                            | ↓ Lytic activity                               | 64        |
| Macrophage       | ↓ M2 Macrophages (pro-tumorigenic)             | NA                                            | Some NSCLC ↑ M2 Macrophages which leads to immune suppression | 60, 61    |

CTLA-4, cytotoxic lymphocyte associated antigen-4; IL-10, interleukin-10; IL-15, interleukin-15; NA, not available; NK, natural killer cells; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; Treg, T-regulatory cells.

**FIGURE 3** | Effect of sarcopenia on immune system function and anti-tumor mechanisms. (A) in individuals without skeletal muscle wasting (no sarcopenia), there is sufficient production and secretion of IL-15 by skeletal muscle cells which in turn can bind to IL-15 receptors on the natural killer (NK) cell surface and T-cells leading to enhanced functional natural killer cell proliferation and maintenance of T-cells including CD8+ T-cells against tumor (69). (B) in the presence of significant muscle wasting (sarcopenia), there is decreased production and secretion of IL-15 by skeletal muscle cells (69), as well as an increased chronic inflammatory status in the body associated with high levels of IL-6 and TGF-β (72–74). The latter can lead to NK suppression through mTOR inhibition leading to dysfunctional NK cell which cannot effectively eliminate malignant cells (63, 64, 75). Decreased IL-15 production can lead as well to impaired maintenance, proliferation, and survival of T-cells which are considered potential targets for immune checkpoint inhibitors.
Tyrosine Kinase Inhibitors, Body Composition, and Outcomes in Non-Small Cell Lung Cancer

Targeted therapy has changed the landscape of the management and prognosis in NSCLC. Targetable alterations in NSCLC include mutations in the epidermal growth factor receptor (EGFR) (accounting for up to 15% NSCLC in Europe and United States, and up to 45% in Southeast Asia) (81, 82), translocation in the anaplastic lymphoma kinase gene (ALK) (accounting for approximately 5% of cases), with a lower frequency of other mutations (ROS1, BRAF, NTRAK, and HER2) (83). Most of the phase 3 randomized controlled trials testing tyrosine kinase inhibitors (TKI) that led to approval of these targeted therapies in patients with NSCLC did not conduct subgroup analyses according to body composition (19, 20, 84). However, evidence suggests that body composition can affect outcomes in patients with NSCLC who harbor EGFR mutation and are treated with EGFR TKIs (85). A retrospective study of 630 patients with metastatic EGFR-mutant NSCLC who received either gefitinib or erlotinib (as first or later line therapy) found a relationship between higher BMI and improved progression free survival (PFS) in patients with BMI $\geq$ 25 kg/m$^2$ compared to BMI < 18.5 kg/m$^2$ (15.6 months versus 8.5 months, respectively) and OS (28.8 months versus 26.7 months, respectively) (85). Multivariate analysis in this study showed BMI as an independent risk factor in terms of PFS and OS (85). Another study used body weight (kg) to estimate PFS and OS in patients with stage IV NSCLC who were treated with gefitinib (cut off point 53 kg) (N = 138) and found a trend towards improved PFS and OS in patients with higher body weight (> 53 kg), however, it was statistically non-significant (86). Lin et al. examined the impact of weight loss prior to starting gefitinib (defined as loss of more than 5% of body weight in a 3 months period before diagnosis) on objective response rate (ORR), PFS and OS. This retrospective analysis included 75 patients and found no difference in ORR but improved PFS in patients with weight loss <5% compared to patients >5% of weight loss (12.4 months versus 7.6 months; hazard ratio [HR] 0.356, 95% confidence interval [CI] 0.212–0.596, $p < 0.001$). This study also reported an improved OS in patients with <5% weight loss compared to those with >5% weight loss (28.5 months vs. 20.7 months, respectively; HR 0.408, 95% CI 0.215–0.776, $p = 0.006$) (87). In contrast, another study in patients with NSCLC who received osimertinib (N= 47) did not show any significant relationship between BMI, PFS, and OS (88). The only study that examined the association of both measures (sarcopenia and BMI) with outcomes in patients with NSCLC and EGFR mutation was a retrospective study of 167 patients who received gefitinib, erlotinib, or afatinib as a first or later line therapy (89). This study showed a BMI $< 18.5$ kg/m$^2$ to be an independent prognostic factor for worse PFS (HR 1.70 [1.03–2.81], $p = 0.04$) and OS (HR 1.72 [1.11–2.67], $p = 0.02$). However, sarcopenia defined by measurements of psoas muscle index (PMI), intermuscular adipose tissue content (IMAC), and visceral to subcutaneous adipose tissue area ratio (VSR) failed to show any effect on different outcomes (89).

Previous discrepancies in the findings of different studies challenge the theory of the effect of body composition on outcomes when NSCLC is treated with EGFR TKI. However, most studies were retrospective and observational in nature and included small sample sizes which could have undermined the relationship between body composition and efficacy of TKIs. The lack of a proposed mechanism supporting a link between body composition and signaling pathways using targetable mutations such as in EGFR mutations poses a question on whether body composition should be examined further as a marker of treatment response in this patient population. However, given the impact of body composition as an independent prognostic factor in NSCLC that have already been established with surgery and chemotherapy and its relationship with altered outcomes in patients treated with different modalities supports the need for further investigation examining these associations. Future studies examining the link between body composition and cancer-related outcomes should consider including the following parameters: better patient selection (i.e., appropriate inclusion and exclusion criteria), larger sample sizes, inclusion of newer medications like osimertinib, as well as accounting for confounding factors such as performance status and metastatic sites (90, 91).

Immune Checkpoint Inhibitors, Body Composition, and Outcomes in Non-Small Cell Lung Cancer

The discovery of immune checkpoint molecules has revolutionized our understanding of tumor biology and resistance mechanisms (92, 93). Immune checkpoints are receptor proteins that are expressed by various immune cells that when bound to their ligands lead to suppression of effector immune cell function (94). Some inhibitory checkpoints can be related to decreased anti-tumor effect against malignant cells which usually use checkpoint ligation to escape immune surveillance (17–19). The two first targetable checkpoint receptors in tumor microenvironment discovered were cytotoxic associated lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) (92, 93). Their discovery led to the development of monoclonal antibodies directed against checkpoint receptors which entered the clinical realm in NSCLC and changed the standard of care after demonstrating improved PFS and OS as first or later line therapy (21–24, 95, 96). However, not all patients retain a good response to these medications with only some patients deriving benefits with a sustained response. This has led to an effort to discover and develop predictive biomarkers to identify appropriate patient selection. Many biomarkers have emerged as predictor markers such as programmed death- ligand 1 expression (PD-L1), tumor mutational burden, and lymphocyte infiltration in tumor bed (97–99). However, adoption of these biomarkers as a conventional method to predict response and survival can be challenging given the lack of standardized definition and methodology used to quantify some of these biomarkers. Thus, the utilization of simpler available patient characteristics such as
gender or body habitus seemed plausible to understand if there is any association with response to immune checkpoint inhibitors (ICI) (98–100).

The prognostic implication of body composition and survival in cancer patients has long been established in different tumor types regardless of stage or treatment approach (33, 101, 102). This concept was later adopted by researchers to examine body composition as a predictive rather than a prognostic marker for response to ICI. Perhaps the earliest link between body composition and survival when using ICI was established in melanoma patients. The work by Daly et al. demonstrated that loss of muscle mass (sarcopenia) can be associated with worse OS in melanoma patients treated with CTLA-4 inhibitors (103). This was followed by other studies that corroborated the findings as a proof of concept and were soon tested in different malignancies including NSCLC (53, 79, 104). There are two different approaches that were used to study the association between body composition and survival. The first was considering the effect of adipose tissue and obesity on survival in patients treated with ICI; while the other approach used skeletal muscle indices as a surrogate for sarcopenia. The feasibility of using such indicators to understand the interconnection was convenient given the simple methodology used to obtain these variables and soon led to several observational and comparative retrospective studies that are summarized in Table 3 (31, 39, 52, 105–113). The findings from retrospective studies seem to be consistent with a trend towards improved PFS and OS in patients with NSCLC treated with PD-1/PD-L1 inhibitors and have been verified with meta-analyses (79, 114). Both high BMI (overweight and obese) and normal SMI (absence of sarcopenia) were associated with improved survival. It should be noted that different cut points were used to identify overweight, obese and sarcopenic patients as these indicators have different established cut points depending on variable factors such as ethnicity and health status (cancer versus no cancer) (26, 33). The use of predictive biomarkers combined with body composition status has proved a stronger correlation than using body composition alone in predicting improved PFS and OS in NSCLC patients treated with ICI in a recent large retrospective study (52). In this important paper, stronger OS/PFS benefit was observed in overweight and obese patients with PD-L1 positive tumors (defined by PD-L1 expression of > 5% of tumor cells or tumor infiltrating immune cells) compared to normal weight patients, which implies that in NSCLC, PD-L1 expression by either tumor cells or by immune cells is critical for OS prediction in obese patients, and obesity is secondary to PD-L1 tumor status (52). Interestingly, evidence suggests that occurrence of immune related adverse events (irAEs) of any grade in different cancer types is higher in overweight and obese patients, while irAEs themselves are associated with improved PFS and OS (114, 115). Therefore, in analyzing the effect of obesity/sarcopenia on survival in NSCLC patients treated with ICI, future studies should consider analyzing the effect of body composition in different subpopulations such as patients with PD-L1 positive tumors, high tumor mutational burden, and also occurrence of irAEs. Limitations that can hinder the robustness of the previously mentioned findings in Table 3 include the retrospective nature of the studies and small sample sizes which are both prone to sampling error and inability to detect a significant difference in specific sub-groups (such as high PD-L1 expression, irAEs).

How to Implement Body Composition Phenotypes in Designing Future Clinical Trials for Patients With Advanced Non-Small Cell Lung Cancer?

Current effort in the management of NSCLC is focused on targeting pathways involved in immune surveillance against tumor cells as well as developing novel drugs against resistant mutations that emerge after exposure to specific targeted therapy. Alongside this effort, it appears to be important to further identify subpopulations who will derive the best benefit. Given the emerging evidence of a crosstalk between different body compositions and cancer biology it will be important to incorporate subgroup analysis in prospective clinical trials when testing current available medication or novel therapies in NSCLC. This would help determine if body composition phenotypes could serve as predictive indicators for the implemented therapies or whether they serve as prognostic factors in NSCLC.

Another area of interest for future research is the changing landscape of cytokine production in obese and sarcopenic NSCLC patient categories and their effect on cancer biology and whether supplementary targeting of specific inflammatory or cytokine pathways could augment the response to immunotherapy. For instance, administration of IL-15 which has been shown to boost anti-tumor immunity in vitro (116). Lastly, it would be intriguing to analyze life style modification such as modulation of nutritional status and exercise or medical interventions to stabilize components of body composition such as lean body mass or adipose tissue and their effect on body composition balance and the outcomes in NSCLC when treated with ICI and other novel therapies. The impact of exercise in improving outcomes has already been established although no focus was put on weight changes as a response to therapy (117). Another example, is the use of anamorelin a ghrelin receptor agonist which maintains lean body mass and has been tested previously for the treatment of cachexia-sarcopenia syndrome in NSCLC (118).

CONCLUSION

In conclusion, the study of body composition as a predictive marker in NSCLC patients treated with novel immune and targeted therapies is an area of compelling interest. Future studies should focus on incorporating subgroup analysis in large prospective trials to better analyze this association. Given that in several studies, obesity plays predictive role among smokers or primarily in PD-L1 positive NSCLC tumors, further studies focusing on BMI among these subsets are warranted. Inclusion of newer promising biomarkers such as...
| Publication          | Sample Size | Male, % | Number of PD-L1 Positive Patients | Immune Checkpoint Inhibitor | Surrogate for Body Composition | Cut-off for Surrogate | End Point | Results*                                                                 | P-Value |
|----------------------|-------------|---------|-----------------------------------|-----------------------------|--------------------------------|-----------------------|-----------|--------------------------------------------------------------------------|---------|
| Kichenadasse et al. (52) | 1434        | 890  (62) | 938 **                            | Atezolizumab                | BMI                            | Per WHO Class         | OS        | Obesity vs. normal weight. HR 0.64 [CI 95%, 0.51-0.81]                    | P < 0.001 |
|                      |             |         |                                   |                             |                                |                       | PFS       | Overweight and obese vs. normal weight HR 0.88 [CI 95%, 0.78-0.99]       | P = 0.03 |
| Cortellini et al. (105) | 976 total with 663 NSCLC cases | 663 (67.9) | NA                               | Pembrolizumab, Nivolumab, Atezolizumab | BMI                            | Overweight/ obese >= 25 vs. non-overweight <25 | ORR       | 41.3 % vs 20.9% 9.3 [95% CI: 8.1-11.6] vs 3.6 [95% CI: 3.2-4.1] months | P < 0.0001 |
|                      |             |         |                                   |                             |                                |                       | TTF       | HR: 0.51 [95% CI: 0.44 - 0.60]                                           | P < 0.0001 |
|                      |             |         |                                   |                             |                                |                       | PFS       | 11.7 [95% CI: 9.4 - 15] vs 3.7 [95% CI: 3.2 - 4.1] months                 | P < 0.0001 |
|                      |             |         |                                   |                             |                                |                       | OS        | 26.6 [95% CI: 21.4 - 36.8] vs 6.6 [95% CI: 5.8 - 8.5] months            | P < 0.0001 |
| Ichihara et al. (106) | Cohort 1: 84 | 68 (80.9) | 84 ***                           | Pembrolizumab               | BMI                            | 22                    | ORR       | 0% complete response 44.6% - partial response, 32.4% - stable disease, 23% progressive disease | |
|                      | Cohort 2: 429 | 338 (78.7) | 45                               | Pembrolizumab, Nivolumab, Atezolizumab | BMI                            |                       | PFS       | 7.3 vs. 4.7 months (HR): 0.94; 95 % CI: 0.53–1.65                        | P = 0.84 |
|                      |             |         |                                   |                             |                                |                       | OS        | NR vs. 17 months HR: 0.67; 95 % CI: 0.32–1.40 (evaluated 403 pts.)      | P = 0.29 |
|                      |             |         |                                   |                             |                                |                       | ORR       | 1.5% complete response, 23.3% partial response, 36.2% stable disease, 3% progressive disease | |
|                      |             |         |                                   |                             |                                |                       | PFS       | 3.7 vs 2.8 months HR: 0.79; 95 % CI: 0.64–0.98                         | P = 0.036 |
|                      |             |         |                                   |                             |                                |                       | OS        | 15.4 vs 13.5 months HR: 0.73; 95 % CI: 0.57–0.95                        | P = 0.021 |
|                      |             |         |                                   |                             |                                |                       | PFS       | High PDL-1 and High BMI vs Low PDL-1 and Low BMI HR: 0.96; 95 % CI: 0.84–1.13 | P = 0.007 |
|                      |             |         |                                   |                             |                                |                       | OS        | 17 vs 3.5 months OS: NR vs 16.1 months HR: 0.73; 95 % CI: 0.57–0.95 | P = 0.031 |
|                      |             |         |                                   |                             |                                |                       | (Continued) |                                                                 |         |

(Continued)
| Publication            | Sample Size | Male, % | Number of PD-L1 Positive Patients | Immune Checkpoint Inhibitor | Surrogate for Body Composition | Cut-off for Surrogate | End Point | Results* | P-Value |
|------------------------|-------------|---------|----------------------------------|-----------------------------|-------------------------------|----------------------|-----------|----------|---------|
| Shiroyama et al. (39)  | 42          | 26      | NA                               | Nivolumab, Pembrolizumab    | PMI Sarcopenia vs non-sarcopenia | Male: 6.36 cm²/m²  | PFS       | 2.1 vs 6.8 months | P = 0.004 |
|                        |             |         |                                  |                             |                               | Female: 3.92 cm²/m² | Overall response rate | 9.1 % vs. 40% | P = 0.025 |
| Nishioka et al. (109)  | 38          | 26      | 16 ****                          | Nivolumab, Pembrolizumab    | Psoas Muscle Major Area change | Change of equal or more than 10% | ORR       | 0 % versus 41% | P = 0.0154 |
|                        |             |         |                                  |                             | Sarcopenia vs non-sarcopenia |                      | PFS       | 47 vs. 204 days [CI 23-76] vs [CI 59-NA] | 0.00186 |
| Katayama et al. (110)  | 35          | 24      | 22****                           | Pembrolizumab, Nivolumab, Atezolizumab | BMI >20                        | PFS       | HR 0.43 [CI 95%, 0.19-0.95] | P = 0.036 |
|                        |             |         |                                  |                             |                               | OS                    | No significant findings | -         |
| Tsukagoshi et al. (111)| 30          | 23      | NA                               | Nivolumab                     | SMI                           | Male: 6.36 cm²/m²  | PFS       | 7.5 vs 2.8 months | P = 0.008 |
|                        |             |         |                                  |                             |                               | Female: 3.92 cm²/m² | OS                    | 25 vs. 10 months | P = 0.03 |
|                        |             |         |                                  |                             | Sarcopenia vs no-sarcopenia   | Male: 52.4 cm²/m²  | Partial response | 35.3% vs 0% | P = r/a |
|                        |             |         |                                  |                             |                               | Female: 38.5 cm²/m² |                      | 2.3 vs 4.1 months | P = 0.56 |
|                        |             |         |                                  |                             | Evolving Sarcopenia           |                      |                      | 7.6 vs. 12.6 months | P = 0.08 |
|                        |             |         |                                  |                             | Similar to definition of cachexia |                      |                      | 2.3 vs 5.1 months | P = 0.04 |
|                        |             |         |                                  |                             | Low SMI vs. high SMI BMI (univariate analysis) |                      |                      | 11.2 vs 15.2 months | P = 0.07 |
| Takada et al. (113)   | 103         | 84      | 25***                            | Nivolumab, pembrolizumab    | SMI                           | Male: 25.63 cm²/m²  | PFS       | HR 1.6 [CI 95%, 1.02- 2.50] | P = 0.0399 |
|                        |             |         |                                  |                             |                               | Female: 21.73 cm²/m² | OS                    | HR 2.04 [CI 95%, 1.14- 3.63] | P = 0.0155 |

* Results reported comparing the higher than cut point group to the lower than cut point group; results are reported as either median PFS, OS or hazard ratios with confidence intervals.

** PD-L1 positivity identified by ≥5%

*** PD-L1 positivity identified by ≥50%

**** PD-L1 >1%

***** Tumor proportion score > 1%

Results are reported across different tumor types of which the majority were non-small cell lung cancer.

BMI, body mass index; CI, confidence interval; HR, hazard ratio; IMAC, Intermuscular adipose content; NA, not available; NR, not reached; PD-L1, programmed death-ligand-1; PFS, progression free survival; PMI, psoas muscle index; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; SMI, skeletal muscle index; SCFM, sub-cutaneous fat mass; TTF, time to treatment failure; WHO, world health organization.
type of EGFR mutations, PD-L1 expression and tumor mutational burden (TMB) in combination with body composition seems plausible. Unifying the definitions and cut points of different surrogate indicators of obesity or sarcopenia can be challenging but would improve our understanding of the effect of obesity and sarcopenia on survival in non-small cell lung cancer patients in the era of precision medicine.

**AUTHOR CONTRIBUTIONS**

KK conceptualized the idea of the manuscript with supervision from YB. KK performed literature search and wrote the manuscript in consultation with YB. KK provided Figures 2, 3 and constructed Tables 1–3. SG-P wrote the section Methods Used in Estimating Body Composition and provided Figure 1. NJ verified the information mentioned in the manuscript and contributed to Tables 2, 3. JP and YB supervised the project. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Himber C, Delpham M, Scherer D, Bowers LW, Hursting S, Ulrich CM. Signals from the adipose microenvironment and the obesity-cancer link: a systematic review. *Cancer Prev Res (Phila)* (2017) 10(9):494–506. doi: 10.1158/1940-6207.CAPR-16-0322
2. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer-Viewpoint of the IARC Working Group. *N Engl J Med* (2016) 373(8):794–8. doi: 10.1056/NEJMo1606602
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* (2003) 348:1625–38. doi: 10.1056/NEJMoa021243
4. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. *Cancer Prev Res (Phila)* (2011) 4(4):486–501. doi: 10.1158/1940-6207.CAPR-10-0229
5. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies. *Ann Oncol* (2014) 25:1901–14. doi: 10.1093/annonc/mdu042
6. Yang L, Yang G, Zhou M, Smith M, Ge H, Boreham J, et al. Body mass index and mortality from lung cancer in smokers and nonsmokers: a nationally representative prospective study of 220,000 men in China. *Int J Cancer* (2009) 125(9):2136–43. doi: 10.1002/ijc.24527
7. Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. *J Surg Res* (2011) 170:75–83. doi: 10.1016/j.jss.2011.04.061
8. Fergusson MK, Im HK, Watson S, Johnson E, Wigfield CH, Vigneswaran WT. Association of body mass index and outcomes after major lung resection. *Eur J Cardiothorac Surg* (2014) 45(4):e94–9. discussion e99. doi: 10.1093/ejcts/ezt008
9. Dahlb erg SE, Schiller JH, Bonomi PB, Sandler AR, Brahm er JR, Ramal ingam SS, et al. Body mass index and its clinical outcomes for advanced non–small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. *J Thorac Oncol* (2013) 8(9):1121–7. doi: 10.1097/ITH.0b013e31829f4942
10. Jeong SM, Lee DH, Giovannucci EL. Predicted lean body mass, fat mass and risk of lung cancer: prospective US cohort study. *Eur J Epidemiol* (2019) 34(12):1151–60. doi: 10.1007/s10654-019-00587-2
11. Buentzl J, Heinz J, Bleckmann A, Bauer C, Röver C, Bohnenberger H, et al. Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis. *Anticancer Res* (2019) 39(9):4603–12. doi: 10.21873/antican.13640
12. Suzuki Y, Okamoto T, Fujishita T, Katsura M, Akamine T, Takamori S, et al. Clinical implications of sarcopenia in patients undergoing complete resection for early non–small cell lung cancer. *Lung Cancer* (2016) 101:92–7. doi: 10.1016/j.lungcan.2016.08.007
13. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2018) 68(6):394–424. doi: 10.3322/caac.21492
14. Yang M, Shen Y, Tan L, Li W. Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. *Chest* (2019) 156(1):101–11. doi: 10.1016/j.chest.2019.04.115
15. Yu D, Zheng W, Johansson M, Lan Q, Park Y, White E, et al. Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis. *J Nucl Cardiol Inot* (2018) 110(8):831–42. doi: 10.1093/jnci/djy286
16. Walunas TL, Lenschow DJ, Bakker CY, Linley PS, Freeman GJ, Green JM, et al. CTLA-4 can function as a negative regulator of T cell activation. *Immunity* (1994) 1(5):405–13. doi: 10.1016/1074-7613(94)90071-x
17. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* (2000) 192(7):1027–34. doi: 10.1084/jem.192.7.1027
18. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahninian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Cil–4. *Science* (1995) 270(5238):985–8. doi: 10.1126/science.270.5238.985
19. Cappuzzo F, Ciuleanu T, Schilsky RL, Cincas S, Szczesna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol* (2010) 11:521–29. doi: 10.1016/S1470-2045(10)70112-1
20. Fukuzuka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (Ipass). *Lancet Oncol* (2011) 12(21):2866–74. doi: 10.1016/S1470-2045(11)70251-X
21. Herbst RS, Bao P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet* (2016) 387(10025):1540–50. doi: 10.1016/S0140-6736(15)01281-7
22. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (IPASS). *Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS).* *Eur J Clin Oncol* (2011) 29(21):2866–74. doi: 10.1200/JCO.2010.33.4235
23. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* (2015) 373(17):1627–39. doi: 10.1056/NEJMoA1507643

**FUNDING**

SG-P is supported by NCI 5R01CA204808-03. YB is supported by NIH R21 CA223394 and NIH R01 CA218802 grants and by the Russian Government Program for Competitive Growth of Kazan Federal University; YB and JP were supported by the NCI Core Grant P30 CA060553 (to Robert H Lurie Comprehensive Cancer Center at Northwestern University).
31. Popinat G, Cousse S, Goldfarb L, Becker S, Gardin I, Salaün M, et al. Subcutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. *Oncoimmunology* (2019) 8(5):e1580128. doi: 10.1080/2162402X.2019.1580128

32. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Psoas muscle area in the assessment of sarcopenia in ovarian cancer. *Support Care Cancer* (2017) 25(7):2353–8. doi: 10.1007/s00520-017-3785-y

33. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Prognostic value of cancer cachexia in non-small cell lung cancer. *Oncoimmunology* (2019) 373(2):123–8. doi: 10.1038/sj.ijo.0800437

34. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Association of Systemic Inflammation Index and Body Mass Index with survival in Patients with Renal Cell Cancer Treated with Nivolumab. *Clin Cancer Res* (2019) 25(13):3839–46. doi: 10.1158/1078-0432.CCR-18-3661

35. Shachar SS, Williams GR, Muss HB, Nishijima TF. Powerful Prognostic Factor, Independent of Body Mass Index. *Future Oncol* (2015) 373(2):123–4. doi: 10.1038/1078-0432.CCR-18-3661

36. Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K, et al. Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index. *J Clin Oncol* (2013) 31:1539–47. doi: 10.1200/JCO.2012.45.2722

37. Singh Mehta G, Seidman MD, Krestanovich AB, Aftab N, Collins JA, et al. The role of body composition in the development of cancer cachexia. *Am J Clin Nutr* (2019) 91(4):1315S–7S. doi: 10.1093/ajcn/91.4.1315S

38. Recio-Boiles A, Galeas JN, Goldwasser B, Sanchez K, Man LMW, Gentzler SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. *Sci Rep* (2019) 9(1):2447. doi: 10.1038/s41598-019-39120-6

39. Baracos VE. Psoas as a sentinel muscle for sarcopenia: a contemporary view of cancer cachexia with the use of computed tomography image analysis. *Am J Clin Nutr* (2010) 91(4):1315S–7S. doi: 10.1093/ajcn/91.4.1315S

40. Baracos VE. Persistent role of psoas muscle in cancer cachexia and the use of computed tomography image analysis. *J Thoracic Oncol* (2012) 7(10):1278–89. doi: 10.1097/JTO.0b013e31825831a4

41. Roddy E, Zhang J, Gao Y, Zhang H, Gao W, Wang G, et al. The diverse roles of adipokines in non-small-cell lung cancer: current data and future perspectives. *Future Oncol* (2020) 15:2193–207. doi: 10.2217/fon.20.1596

42. Zhan SX, Liu Y, Shao H, Zheng X. Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications. *J Thoracic Oncol* (2017) 12(10):1478–88. doi: 10.1016/j.jtho.2017.07.022

43. Wang Z, Aguilar EG, Luna JL, Dunai C, Khuatt LT, Le CT, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. *Nat Med* (2019) 25(1):141–51. doi: 10.1038/s41598-018-0221-5

44. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. *Semin Oncol* (2010) 37(5):430–9. doi: 10.1053/j.seminoncol.2010.09.005

45. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* (2018) 19(3):310–22. doi: 10.1016/S1470-2045(18)30078-0

46. Kichendasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. *JAMA Oncol* (2019) 6(4):512–8. doi: 10.1001/jamaoncol.2019.5241

47. Bhat J, Saini K, Panigrahi D, Solanki N, Kachroo N, Khera M, et al. Natural killer cell subset phenotypes in human obesity. *J Immunol* (2014) 192(2):623–9. doi: 10.4049/jimmunol.1302181

48. Hurwitz A, Keshavarz P, Dhillon A, Tincani E, Logan C, et al. Profound coordinated alterations of intratumoral NK cell phenotype in CD56 bright CD16(-) cells and display an impaired capability to kill melanoma targets. *J Immunol* (2013) 190(10):4975–83. doi: 10.4049/jimmunol.1302181

49. Hashish A, Gill J, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs. *JAMA Netw Open* (2020) 3(3):e200423. doi: 10.1001/jamanetworkopen.2020.0423

50. Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R, et al. Defining obesity cut points in a multietnic population. *Circulation* (2007) 115(16):2111–8. doi: 10.1161/CIRCULATIONAHA.106.635011

51. Kovarik M, Hronek M, Zadak Z. Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients. *Lung Cancer* (2014) 84(1):1–6. doi: 10.1016/j.lungcan.2014.01.020

52. Razak F, Anand SS, Shannon H, Vuksan V, Davis B, Jacobs R, et al. Defining obesity cut points in a multietnic population. *Circulation* (2007) 115(16):2111–8. doi: 10.1161/CIRCULATIONAHA.106.635011

53. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Association of Systemic Inflammation Index and Body Mass Index with survival in Patients with Renal Cell Cancer Treated with Nivolumab. *Clin Cancer Res* (2019) 25(13):3839–46. doi: 10.1158/1078-0432.CCR-18-3661

54. Han JM, Patterson SJ, Speck M, Eshes J, Leving KS. Infiltration inhibits IL-10-mediated regulatory T cell function: implications for obesity. *J Immunol* (2014) 192(2):623–9. doi: 10.4049/jimmunol.1302181

55. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. *Lancet Oncol* (2018) 19(3):310–22. doi: 10.1016/S1470-2045(18)30078-0
61. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer (2010) 10:220. doi: 10.1186/1471-2407-10-220
62. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin-15-deficient mice. J Exp Med (2000) 191(5):771–80. doi: 10.1084/jem.191.5.771
63. Carson WE, Giri JG, Lindemann ML, Linnett ML, Ahdieh M, Paxton R, et al. The Mechanism of reversible defects in natural killer and memory CD8 T cell lineages in interleukin-15-deficient mice. Oncotarget (2015) 6(42):4123–33. doi: 10.18632/oncotarget.6536
64. Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, et al. The Mechanism of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients. Int Immunopharmacol (2019) 74:105745. doi: 10.1016/j.intimp.2019.105745
65. Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C, et al. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report. Thorac Cancer (2019) 10(2):347–51. doi: 10.1111/1759-7714.12965
66. Van den Bergh J, Willemen Y, Lion E, Van Acker H, De Reu H, Anguille S, et al. Different aspects of skeletal muscle as a potential central link between sarcopenia and immune senescence. Front Immunol (2017) 8:516. doi: 10.3389/fimmu.2017.00527
67. Argile J, Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different immunological hallmarks of human tumor-infiltrating lymphocytes. J Exp Med (2004) 200(12):670–6. doi: 10.1084/jem.2004.09.008
68. Carrega P, Ferlazzo G. Natural Killers Are Made Not Born: How to Exploit Immune Checkpoints on Innate Lymphoid Cells. Int J Biochem Cell Biol (2005) 37(5):1084–104. doi: 10.1016/j.jibc.2004.10.003
69. Nebey C, Drieuas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as a potential central link between sarcopenia and immune senescence. EBioMedicine (2019) 49:381. doi: 10.1016/j.ebiom.2019.10.034
70. Nielsen AR, Mounier R, Plomgaard P, Mortensen OH, Penkowa M, Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as a potential central link between sarcopenia and immune senescence. EBioMedicine (2019) 49:381. doi: 10.1016/j.ebiom.2019.10.034
71. Nebey C, Drieuas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as a potential central link between sarcopenia and immune senescence. EBioMedicine (2019) 49:381. doi: 10.1016/j.ebiom.2019.10.034
72. Nebey C, Drieuas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as a potential central link between sarcopenia and immune senescence. EBioMedicine (2019) 49:381. doi: 10.1016/j.ebiom.2019.10.034
Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taou
Daly LE, Power DG, O
Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, et al.
Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer
Minami S, Ihara S, Tanaka T, Komuta K. Sarcopenia and Visceral Adiposity
Ichihara E, Harada D, Inoue K, Sato K, Hosokawa S, Kishino D, et al. The
Nishioka N, Uchino J, Hirai S, Katayama Y, Yoshimura A, Okura N, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Med (Baltimore) (2020) 99(7):e19059. doi: 10.1097/MD.DO.00000000000019059
Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, et al. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer (2020) 143:19–26. doi: 10.1016/j.lungcan.2020.03.003
Takada K, Yoneshima Y, Tanaka K, Okamoto I, Shimokawa M, Wakasu S, et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J Cancer Res Clin Oncol (2020) 146(5):1217–25. doi: 10.1007/s00432-020-03146-5
Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med (2020) 18(1):87. doi: 10.1186/s12916-020-01549-2
Corbellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, et al. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer (2020) 128:17–26. doi: 10.1016/j.ejca.2019.12.031
Berger A, Colpitts SJ, Seabrook MSS, Furlonger CI, Bendix MB, Moreau JM, et al. Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model. J Immunother Cancer (2019) 7(1):355. doi: 10.1186/s40425-019-0777-8
Peddle-McIntyre CJ, Singh F, Thomas R, Newton RU, Galvão DA, Cavalheri V. Exercise training for advanced lung cancer. Cochrane Database Syst Rev (2019) 2(2):CD012685. doi: 10.1002/14651858.CD012685.pub2
Zhang H, Garcia JM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother (2015) 16(8):1245–53. doi: 10.1517/14656566.2015.1041300
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Khaddour, Gomez-Perez, Jain, Patel and Boumber. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.